Skip to main content

Angeles Alvarez Secord

Professor of Obstetrics and Gynecology
Obstetrics and Gynecology, Gynecologic Oncology
Box 3079 Med Ctr, Durham, NC 27710
25172 Morris Bldg, Durham, NC 27710

Research Interests


My research interests include innovative clinical trial design, development of novel targeted therapies for personalized medicine, identification of biomarkers to direct anti-neoplastic therapy, and the incorporation of patient-reported outcomes in clinical trials. She has studied the regulation of angiogenesis in ovarian cancer for approximately 20 years and has recently extended our research to include the immunophenotype of the tumor microenvironment.

Selected Grants


Building Interdisciplinary Research Careers in Women's Health - BIRCWH

Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2002 - 2027

A Phase IB/II Multi-Cohort Study of Targeted Agents with Atezolizumab for Patients with Recurrent or Persistent Endometrial Cancer

Clinical TrialPrincipal Investigator · Awarded by Alliance Foundation Trials, LLC · 2022 - 2026

NCORP federal

Clinical TrialPrincipal Investigator · Awarded by NRG Oncology · 2019 - 2026

NRG ONCOLOGY NETWORK GROUP OPERATIONS CENTER

ResearchPrincipal Investigator · Awarded by NRG Oncology · 2017 - 2026

NCTN - NCORP non-federal

Clinical TrialPrincipal Investigator · Awarded by NRG Oncology · 2016 - 2026

Duke Women's Reproductive Health Research Scholars

Inst. Training Prgm or CMEMentor · Awarded by Eunice Kennedy Shriver National Institute of Child Health and Human Development · 2020 - 2025

NCI National Clinical Trials Network (UG1)

Clinical TrialCo-Principal Investigator · Awarded by National Institutes of Health · 2019 - 2025

NRG NCTN/NCORP - DoD

Clinical TrialPrincipal Investigator · Awarded by NRG Oncology · 2019 - 2025

FRa expression in Endometrial Cancer

ResearchPrincipal Investigator · Awarded by ImmunoGen, Inc. · 2023 - 2024

Redox-active drug, BMX-001, as a neuroprotectant: A preventive strategy for chemotherapy induced neurotoxicity

ResearchPrincipal Investigator · Awarded by Health and Environmental Sciences Institute · 2022 - 2024

Molecular classification of endometrial cancers and association with survival outcomes: GOG-0258

ResearchPrincipal Investigator · Awarded by OhioHealth Research Institute · 2022 - 2024

Clovis CO3810-101

Clinical TrialPrincipal Investigator · Awarded by Clovis Oncology, Inc. · 2020 - 2024

A Pilot Study Investigating the Effect of Pembrolizumab on the Tumoral Immunoprofile of Cancers of Muellerian Origin

ResearchPrincipal Investigator · Awarded by Merck Sharp & Dohme · 2016 - 2022

Molecular classification of endometrial advanced stage cancers and association with survival outcomes: Ancillary analysis of GOG-0258

ResearchPrincipal Investigator · Awarded by American Association of Obstetricians and Gynecologists Foundation · 2021 - 2022

TESARO LUNG AND ENDOMETRIAL CANCER PRACTICUM

Inst. Training Prgm or CMECo-Principal Investigator · Awarded by TESARO · 2019 - 2019

Women with BRCA-mutated Advanced Stage Ovarian Cancer

ResearchCo Investigator · Awarded by AstraZeneca LP · 2017 - 2019

Phase 2 Trial of Dose Dense (Weekly) Paclitaxel with Pembrolizumab (MK-3475) in Platinum Resistant Recurrent Ovarian Cancer

Clinical TrialPrincipal Investigator · Awarded by H. Lee Moffitt Cancer Center & Research Institute · 2016 - 2019

NCI National Clinical Trials Network U10 (Year 5)

Clinical TrialCo-Principal Investigator · Awarded by National Institutes of Health · 2014 - 2019

Predictive value of the IL6 pathway to direct anti-angiogenic therapy in advanced ovarian cancer

ResearchPrincipal Investigator · Awarded by American Association of Obstetricians and Gynecologists Foundation · 2017 - 2018

Assessing the relevance of weighted values in the ASCO value framework in ovarian cancer patients

ResearchInvestigator · Awarded by Gynecologic Oncology Group · 2016 - 2017

Biomarker Discovery to Direct Bevacizumab Therapy in Ovarian Cancer - Blood-based Angiome Profiling

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2014 - 2017

Tesaro Ovarian Cancer Practicum

Inst. Training Prgm or CMEPrincipal Investigator · Awarded by TESARO · 2016 - 2016

External Relationships


  • AAOGF
  • AbbVie, Inc.
  • Aravive
  • GOG Foundation Board
  • GSK
  • Genentech, Inc (Roche Holding)
  • OncoQuest - Quest Pharma
  • SGO
  • VBL Therapeutics

This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.